Liminatus Pharma Inc share price logo

Liminatus Pharma Inc Share Price

NASDAQ: LIMN

Mid Cap

$1.29

-0.02

(-1.53%)

Live

as on

Liminatus Pharma Inc Stock Performance

as on November 7, 2025 at 12:36 am IST

  • Day's Low

    Day's High

    $1.24
    $1.32
    downward going graph

    3.88%

    Downside

    2.33%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.11
    $33.66
    downward going graph

    13.95%

    Downside

    2509.30%

    Upside

    downward going graph

Liminatus Pharma Inc share price movements today

Previous Close
$1.31
Open
$1.29
Volume
366.2K
Day's Low - High
$1.24 - $1.32
52 Week Low - High
$1.11 - $33.66

Liminatus Pharma Inc Historical Returns

1 Month Return
-24.28 %
3 Month Return
-72.13 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Liminatus Pharma Inc Stock Fundamentals & Key Indicators

Check Liminatus Pharma Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$145.2M

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Liminatus Pharma Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Liminatus Pharma Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Liminatus Pharma Inc image
Liminatus Pharma Inc
NA$145.2MNANA0.00%
Insmed Incorporated image
Insmed Incorporated
BUY$39.9B473.78%-16.34-264.83%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$55.9B232.41%1411.571.36%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$108.1B89.3%29.6331.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$67.5B11.45%15.3832.13%

Liminatus Pharma Inc Stock’s Investor Sentiment and Interest

Search interest for Liminatus Pharma Inc Stock has decreased by -71% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-71% versus previous 30 day period

Liminatus Pharma Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Mar 2025
Total Revenue
-
-
-
Gross Profit
-
-
-
Operating Income
0
-1
0
EBITDA
0
-1
0
Interest Expense
0
0
-
Depreciation
-
-
-
Income Before Tax
0
-1
0
Income Tax Expense
0
-
-
Net Income
0
-1
0
Net Profit Margin
0.00%
0.00%
0.00%

Liminatus Pharma Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Total Revenue
-
-
Gross Profit
-
-
Operating Income
-2
-2
EBITDA
-2
-4
Interest Expense
0
0
Depreciation
-
-
Income Before Tax
-2
-1
Income Tax Expense
0
0
Net Income
-2
-4
Net Profit Margin
0.00%
0.00%

Liminatus Pharma Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Sep 2025
Net Income
734
-858
0
0
0
0
0
Operating Cash Flow
0
-903
0
0
0
-
-8
Investing Cash Flow
0
248
1
0
0
-
0
Financing Cash Flow
9,913
700
0
0
0
-
11
Change in Cash
-337
45
-1
0
0
-
1

Liminatus Pharma Inc Annual Cash Flow

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Net Income
-2
-4
-2
Operating Cash Flow
-1
-3
-3
Investing Cash Flow
263
0
1
Financing Cash Flow
-262
0
1
Change in Cash
0
-4
0

Insights on Liminatus Pharma Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, LIMN stock has moved down by -24.3%

About Liminatus Pharma Inc

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
OrganisationLiminatus Pharma Inc
Headquarters6 Centerpointe Drive, La Palma, CA, United States, 90623
CEOMr. Chris Kim J.D., L.L.M.
E-voting on sharesClick here to vote

Key Management of Liminatus Pharma Inc

Name

Title

Dr. Beom Kyu Choi

Chief Technology Officer & Member of Scientific Advisory Board

Dr. Byong Chul Yoo Ph.D.

Chief Science Officer & Member of Scientific Advisory Board

Dr. Sang-jin Lee Ph.D.

Head of Research & Development and Member of Scientific Advisory Board

Mr. Chris Kim J.D., L.L.M.

CEO & Chairman

Mr. Scott Dam

Chief Financial Officer

FAQs

What is Liminatus Pharma Inc share price today?

Liminatus Pharma Inc share price today is $1.29 as on . Liminatus Pharma Inc share today touched a day high of $1.32 and a low of $1.24.

What is the 52 week high and 52 week low for Liminatus Pharma Inc share?

Liminatus Pharma Inc share touched a 52 week high of $33.66 on and a 52 week low of $1.11 on . Liminatus Pharma Inc stock price today i.e. is trending at $1.29,which is 96.17% down from its 52 week high and 16.22% up from its 52 week low.

What is Liminatus Pharma Inc's market capitalisation today?

Liminatus Pharma Inc market capitalisation is $0.00T as on .

How to invest in Liminatus Pharma Inc Stock (LIMN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Liminatus Pharma Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Liminatus Pharma Inc Shares that will get you 1.1628 shares as per Liminatus Pharma Inc share price of $1.29 per share as on November 7, 2025 at 12:36 am IST.

What is the minimum amount required to buy Liminatus Pharma Inc Stock (LIMN) from India?

Indian investors can start investing in Liminatus Pharma Inc (LIMN) shares with as little as ₹88.566 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹885.66 in Liminatus Pharma Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Liminatus Pharma Inc share’s latest price of $1.29 as on November 7, 2025 at 12:36 am IST, you will get 7.7519 shares of Liminatus Pharma Inc. Learn more about fractional shares .